Cardiff Oncology Stock Craters Amid Executive Exits and Mixed Mid-Stage Data

Cardiff Oncology's stock fell 32% to $2 after releasing mixed Phase II data for onvansertib and announcing the departure of CEO Mark Erlander and CFO James Levine.1 3

The 30mg dose of onvansertib with FOLFIRI plus bevacizumab reduced risk of death or progression by 62% vs standard care, but wide confidence intervals and lack of detailed data raised analyst concerns; company advancing to Phase 3 trial in 2026.1 2

Mani Mohindru appointed interim CEO and Brigitte Lindsay promoted to chief accounting officer; permanent replacements being sought.1

Company had $60 million cash as of Q3 2025, likely needing funding for pivotal study; secured $15M from Pfizer, runway to Q1 2027.1 2

Analysts at William Blair noted data 'slants negative' but are intrigued, awaiting detailed release and explanations for regimen differences.1

Sources:

1. https://www.biospace.com/drug-development/cardiff-craters-amid-executive-exits-mixed-mid-stage-data

2. https://www.ainvest.com/news/cardiff-oncology-2026-pipeline-catalysts-balancing-therapeutic-promise-regulatory-commercial-realities-2601/

3. https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3YS1DX:0-cardiff-oncology-plunges-after-top-executives-step-down/

Sources:

Leave a Reply Cancel reply